Skip to main content
BALAXI PHARMACEUTICALS LIMITED logo

BALAXI PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · BALAXI ISIN · INE618N01022 LEI · 894500VRENAYIIWHHQ13 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 615 across all filing types
Latest filing 2024-08-02 Capital/Financing Update
Country IN India
Listing National Stock Exchange of India BALAXI

About BALAXI PHARMACEUTICALS LIMITED

https://www.balaxipharma.in/

Balaxi Pharmaceuticals Limited is a specialty pharmaceutical company that operates an asset-light business model focused on sourcing, branding, and distributing generic formulations in frontier markets. The company primarily serves emerging economies across Africa and Latin America, including Angola, Guatemala, and the Dominican Republic. Its product portfolio encompasses a wide range of therapeutic segments such as anti-infectives, analgesics, and antimalarials. Balaxi manages an integrated supply chain, leveraging its regulatory expertise to register and market high-quality pharmaceutical products. By maintaining a robust distribution network and localized presence, the company ensures the availability of essential medicines in underserved regions while optimizing operational efficiency through its specialized procurement and logistics framework.

Recent filings

Filing Released Lang Actions
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document is a statement addressed to the National Stock Exchange of India regarding the deviation or variation in the utilization of funds raised through a preferential issue for the quarter ended June 30, 2024. It references SEBI regulations and provides detailed information about the fund raising, utilization, and any deviations. The content is a regulatory compliance disclosure related to capital raising activities, specifically about the use of funds from a preferential issue. It is not a full financial report, audit report, or earnings release, but rather an update on capital utilization tied to financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information, so it is not merely an announcement or certification but a detailed update on capital usage.
2024-08-02 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is dated August 2, 2024, and contains detailed unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. It includes financial tables with income, expenses, profit, and earnings per share data. The document also contains an Independent Auditor's Review Report pursuant to SEBI regulations, indicating a limited review rather than a full audit. The presence of quarterly financial data and the limited review report aligns with an Interim / Quarterly Report. The document is substantive and contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-08-02 English
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is dated August 2, 2024, and contains detailed unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. It includes financial tables with income, expenses, profit, and earnings per share data. The document also contains an Independent Auditor's Review Report pursuant to SEBI regulations, which is typical for quarterly financial disclosures. The presence of detailed financial data and the auditor's review confirms this is a quarterly financial report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-08-02 English
Copy of Newspaper Publication
Regulatory Filings
2024-08-01 English
Updates
Environmental & Social Information Classification · 95% confidence The document is titled 'Business Responsibility and Sustainability Report for FY 2023-24' and is submitted pursuant to SEBI regulations. It includes detailed disclosures on environmental, social, governance (ESG) factors, employee data, CSR details, and sustainability policies. The report is part of the Annual Report but focuses specifically on sustainability and business responsibility aspects. It is a comprehensive report on ESG performance rather than a general financial or management report. This matches the definition of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is SR with high confidence.
2024-07-31 English
Shareholders meeting
AGM Information Classification · 95% confidence The document is a Notice of the 81st Annual General Meeting (AGM) of Balaxi Pharmaceuticals Limited scheduled for August 23, 2024. It includes details about the AGM date, time, venue (virtual), agenda items such as adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2024, re-appointment of a director, voting instructions, and regulatory compliance references. The document is primarily a formal notice inviting shareholders to the AGM and providing procedural information, not the full Annual Report or financial statements themselves. It also references that the Annual Report 2023-24 is available on the company's website but does not contain the report itself. The length (15,000 characters) is consistent with a detailed AGM notice. Therefore, this document fits the category of AGM Information (AGM-R).
2024-07-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.